Hima Bindu Musunuru1, Toshihiro Yamamoto2, Laurence Klotz2, Gabriella Ghanem3, Alexandre Mamedov3, Peraka Sethukavalan3, Vibhuti Jethava2, Suneil Jain4, Liying Zhang3, Danny Vesprini1, Andrew Loblaw5. 1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. 2. Department of Surgical Urology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 3. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 4. Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland. 5. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Measurement and Evaluation, University of Toronto, Toronto, Ontario, Canada. Electronic address: andrew.loblaw@sunnybrook.ca.
Abstract
PURPOSE: To assess the applicability of active surveillance in patients with intermediate risk prostate cancer, we compared the survival outcomes of patients with low risk and intermediate risk disease. MATERIALS AND METHODS: Active surveillance was offered to all patients with low risk (cT1-T2b and Gleason score 6 and prostate specific antigen 10 ng/ml or less) and select intermediate risk disease (age greater than 70 years with cT2c or prostate specific antigen 15 ng/ml or less, or Gleason score 3+4 or less). Data from November 1995 to May 2013 were extracted from a prospectively collected database. The primary outcome was metastasis-free survival, and secondary outcomes were overall survival, cause specific survival and treatment-free survival. RESULTS: A total of 213 intermediate risk and 732 low risk cases were identified. Median age was 72 years (IQR 67.3, 76.8) in the intermediate risk cohort and 67 years (IQR 60.6, 71.9) in the low risk group. Median followup was comparable (6.7 years for intermediate risk vs 6.5 years for low risk). Gleason 7 disease comprised 60% of the intermediate risk cohort. The 15-year metastasis-free, overall, cause specific and treatment-free survival rates were inferior in the intermediate risk group (metastasis-free survival HR 3.14, 95% CI 1.51-6.53, p=0.001, 82% for intermediate risk vs 95% for low risk). On further evaluation the estimated 15-year metastasis-free survival for cases of Gleason 6 or less with prostate specific antigen less than 10 ng/ml was 94%, Gleason 6 or less with prostate specific antigen 10 to 20 ng/ml was 94%, Gleason 3+4 with prostate specific antigen 20 ng/ml or less was 84% and Gleason 4+3 with prostate specific antigen 20 ng/ml or less was 63%. CONCLUSIONS: These data support the use of active surveillance in low risk and intermediate risk cases of Gleason 6 but not Gleason 7 prostate cancer. Multiparametric magnetic resonance imaging and novel biomarkers might be vital in detecting favorable Gleason 7 disease.
PURPOSE: To assess the applicability of active surveillance in patients with intermediate risk prostate cancer, we compared the survival outcomes of patients with low risk and intermediate risk disease. MATERIALS AND METHODS: Active surveillance was offered to all patients with low risk (cT1-T2b and Gleason score 6 and prostate specific antigen 10 ng/ml or less) and select intermediate risk disease (age greater than 70 years with cT2c or prostate specific antigen 15 ng/ml or less, or Gleason score 3+4 or less). Data from November 1995 to May 2013 were extracted from a prospectively collected database. The primary outcome was metastasis-free survival, and secondary outcomes were overall survival, cause specific survival and treatment-free survival. RESULTS: A total of 213 intermediate risk and 732 low risk cases were identified. Median age was 72 years (IQR 67.3, 76.8) in the intermediate risk cohort and 67 years (IQR 60.6, 71.9) in the low risk group. Median followup was comparable (6.7 years for intermediate risk vs 6.5 years for low risk). Gleason 7 disease comprised 60% of the intermediate risk cohort. The 15-year metastasis-free, overall, cause specific and treatment-free survival rates were inferior in the intermediate risk group (metastasis-free survival HR 3.14, 95% CI 1.51-6.53, p=0.001, 82% for intermediate risk vs 95% for low risk). On further evaluation the estimated 15-year metastasis-free survival for cases of Gleason 6 or less with prostate specific antigen less than 10 ng/ml was 94%, Gleason 6 or less with prostate specific antigen 10 to 20 ng/ml was 94%, Gleason 3+4 with prostate specific antigen 20 ng/ml or less was 84% and Gleason 4+3 with prostate specific antigen 20 ng/ml or less was 63%. CONCLUSIONS: These data support the use of active surveillance in low risk and intermediate risk cases of Gleason 6 but not Gleason 7 prostate cancer. Multiparametric magnetic resonance imaging and novel biomarkers might be vital in detecting favorable Gleason 7 disease.
Authors: Jouhyun Jeon; Ekaterina Olkhov-Mitsel; Honglei Xie; Cindy Q Yao; Fang Zhao; Sahar Jahangiri; Carmelle Cuizon; Seville Scarcello; Renu Jeyapala; John D Watson; Michael Fraser; Jessica Ray; Kristina Commisso; Andrew Loblaw; Neil E Fleshner; Robert G Bristow; Michelle Downes; Danny Vesprini; Stanley Liu; Bharati Bapat; Paul C Boutros Journal: J Natl Cancer Inst Date: 2020-03-01 Impact factor: 13.506
Authors: Marco Bandini; Raisa S Pompe; Michele Marchioni; Zhe Tian; Giorgio Gandaglia; Nicola Fossati; Derya Tilki; Markus Graefen; Francesco Montorsi; Shahrokh F Shariat; Alberto Briganti; Fred Saad; Pierre I Karakiewicz Journal: World J Urol Date: 2017-10-23 Impact factor: 4.226
Authors: Kathleen F McGinley; Xizi Sun; Lauren E Howard; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Stephen J Freedland Journal: Int J Urol Date: 2017-06-06 Impact factor: 3.369
Authors: Ariel A Schulman; Christina Sze; Efrat Tsivian; Rajan T Gupta; Judd W Moul; Thomas J Polascik Journal: Curr Urol Rep Date: 2017-07 Impact factor: 3.092
Authors: Inderbir S Gill; Abdel-Rahmene Azzouzi; Mark Emberton; Jonathan A Coleman; Emmanuel Coeytaux; Avigdor Scherz; Peter T Scardino Journal: J Urol Date: 2018-06-02 Impact factor: 7.450
Authors: Sigrid Carlsson; Nicole Benfante; Ricardo Alvim; Daniel D Sjoberg; Andrew Vickers; Victor E Reuter; Samson W Fine; Hebert Alberto Vargas; Michal Wiseman; Maha Mamoor; Behfar Ehdaie; Vincent Laudone; Peter Scardino; James Eastham; Karim Touijer Journal: J Urol Date: 2020-01-07 Impact factor: 7.450